← Back to Portfolio

Avillion II (AZ)

Avillion is focused on clinical co-development and financing of late-stage therapeutics. The company has formed a deal with AstraZeneca to develop and finance a potential asthma therapy through clinical trials to regulatory approval. PT027 is a fixed dose combination of two drugs that are being co-administered for the first time via a new inhaler technology. The drugs comprise an anti-inflammatory steroid, budesonide, and a bronchodilator, albuterol, a short-acting beta-2 agonist. The inhaler is designed and manufactured by Pearl Therapeutics, a subsidiary of AZ.

LocationLondon, UK
CEOAllison Jeynes-Ellis
Partner Genghis Lloyd-Harris
Websitewww.avillionllp.com